La Jolla Pharmaceutical Company to Provide Corporate Overview at the 2016 BIO CEO & Investor Conference

La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the Company will provide a corporate overview at the 2016 BIO CEO & Investor Conference taking place February 8–9 in New York City.

2016 BIO CEO & Investor Conference Presentation Details

    
      
        
           
        
      
      
        
          Date:
        
        
           
        
        
           
        
        
           
        
        
          Monday, February 8, 2016
        
      
      
        
          Time:
        
        
        
        
        
        
        
        
          3:30 p.m. Eastern Time
        
      
      
        
          Location:
        
        
        
        
        
        
        
        
          Conrad Room @ Waldorf Astoria Hotel New York
        
      
      
        
          Webcast:
        
        
        
        
        
        
        
        
          

LJPC Webcast Link

A live webcast of the presentation will also be available in the Investor Relations section of La Jolla’s website at www.ljpc.com. A replay of the presentation will be available on La Jolla’s website for 30 days following the event.

About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has several product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia and sickle cell disease. LJPC-30Sa and LJPC-30Sb are Jolla’s next-generation gentamicin derivatives for the potential treatment of serious bacterial infections and rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy. For more information on La Jolla, please visit www.ljpc.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160129005233/en/

La Jolla Pharmaceutical CompanyGeorge F. Tidmarsh, M.D., Ph.D.President & Chief Executive Officer(858) [e-mail] M. MulroyChief Financial Officer(858) [e-mail]